Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 9/20 | 0.45 |
| ▸ | MMP3 | P08254 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740070 | 0.85 | MMP8 (0.43) | ACEMMP8MMP3 | |
| SCHEMBL7536956 | 0.82 | ACE (0.49) | ACEALDH1A1LMNAMMP8MMP3 | |
| SCHEMBL7536950 | 0.82 | ACE (0.49) | ACEALDH1A1LMNAMMP8MMP3 | |
| SCHEMBL12191655 | 0.79 | ACE (0.51) | ACEALDH1A1LMNAMMP8MMP3 | |
| SCHEMBL7536221 | 0.78 | GRM2 (0.51) | ACEMMP8MMP3MMP13 | |
| SCHEMBL7536224 | 0.78 | GRM2 (0.51) | ACEMMP8MMP3MMP13 | |
| SCHEMBL5500239 | 0.77 | HTR2A (0.47) | ACEALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6962899 | 0.76 | HTR2A (0.46) | ACEALDH1A1LMNA | |
| SCHEMBL9631439 | 0.76 | ACE (0.50) | ACEALDH1A1LMNAPOLBTDP1 | |
| SCHEMBL12125023 | 0.76 | ACE (0.53) | ACEALDH1A1LMNAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
| CN-101597196-A | Improved drug candidate and preparation method thereof | BELLUS HEALTH INTERNAT LTD (CH) | 2009-12-09 | — | — | CN | disclosed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | disclosed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | disclosed |
| CN-100528840-C | Improved drug candidates and methods for their preparation | NEUROCHEM INTERNAT LTD (CH) | 2009-08-19 | — | — | CN | disclosed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
| US-7244764-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-07-17 | — | — | US | disclosed |
| US-7244764-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-07-17 | — | — | US | disclosed |
| CN-1839117-A | Improved drug candidates and methods for their preparation | NEUROCHEM INTERNAT LTD (CH) | 2006-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | APP, PSEN1, PSEN2 | ACE 47/4885ALDH1A1 2926/4885LMNA 74/4885 |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | ACE 47/4885ALDH1A1 2926/4885LMNA 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.